SBIR-STTR Award

Obese Diabetic (Type Ii) Mouse Model Without Leptin/Leptin-Receptor Defects
Award last edited on: 9/20/13

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$1,485,419
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Richard G Peterson

Company Information

PreClinOmics Inc (AKA: PCO)

7918 Zionsville Road
Indianapolis, IN 46268
   (317) 872-6001
   N/A
   www.preclinomics.com
Location: Single
Congr. District: 05
County: Marion

Phase I

Contract Number: 1R43DK082065-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2008
Phase I Amount
$148,453
An estimated 18.2 million people (6.3 percent of the population) in the United States have diabetes; 90 to 95 percent of all diagnosed cases are type II diabetes (NIDDK, 2005). Obesity and metabolic syndrome are the leading causes of type II diabetes. The search for new and more effective therapies to address the growing number of Americans with type II diabetes and related conditions is currently hindered by the lack of an obese research animal model that closely resembles the conditions that lead to the human type II diabetic condition. Most rodent models currently available commercially, related to obesity, metabolic syndrome and type II diabetes, have genetic defects in leptin-receptors, leptin or in other hypothalamic peptides. These defects are not common causes for the etiology of obesity and diabetes in the human population. A new mouse model without these defects would more closely resemble the human condition and thus be more appropriate for the study of diabetic-related conditions and metabolic syndrome. PreClinOmics (PCO) has begun to develop a new mouse model without leptin/leptin-receptor and other genetic defects, which would affect hypothalamic function, by crossing two inbred mouse models with the propensity to develop diet induced obesity with insulin resistance. The long-term goal of this project is to create a mouse model that will be accepted by the biotech or pharmaceutical industries, and the research community to advance the study and development of obesity and type II diabetic therapies in humans. Phase I of the project will focus on the continued development, defining, and characterization of this new obese mouse model. The project has four specific aims. First, continue the development of a mouse model (Fatzo) for obesity, metabolic syndrome, and type II diabetes without leptin/leptin-receptor defects using both phenotypic and genetic monitoring to achieve phenotypic and genetic homogeneity. Second, investigate the effects of diet manipulation on the onset, consistency and synchronicity of the phenotypic expression (obesity and type II diabetes). Third, demonstrate the efficacy of typical anti-obesity/anti-diabetic compounds on the reversal of obesity and prevention of diabetes to show the utility of this mouse model. Fourth, examine the effect of leptin on food consumption in Fatzo and control strains.

Public Health Relevance:
: Current commercially available animal models that are used for obesity, metabolic syndrome and diabetes research and drug development have leptin and leptin-related genetic defects that cause obesity. These defects are not found in the typical obese and diabetic individuals where multiple genes seem to be responsible for the condition. The purpose of this project is to develop and produce a new obese and diabetes-prone mouse model which has multiple contributing genetic factors but without a leptin or leptin receptor defect. This will be a very important model for the development of drugs that will control obesity and adult onset diabetes.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: 2R44DK082065-02A1
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2012
(last award dollars: 2013)
Phase II Amount
$1,336,966

An estimated 23.6 million people (7 percent of the population) in the United States have diabetes;90 to 95 percent of all diagnosed cases are type 2 diabetes (CDC, 2007). Obesity and metabolic syndrome are the leading causes of type 2 diabetes. The search for new and more effective therapies to address the growing number of Americans with type 2 diabetes and related conditions is currently hindered by the lack of a research animal model that closely resembles the conditions such as obesity and metabolic syndrome that lead to the human type 2 diabetic condition. Most rodent models currently available commercially that have obesity, metabolic syndrome and type 2 diabetes, have genetic defects in leptin-receptors, leptin or in other hypothalamic peptides. These mono-genetic defects are not common causes for the etiology of obesity and diabetes in the human population. A new mouse model without these defects would more closely resemble the continuum of metabolic disorders that is beginning to be recognized between these human conditions. Thus, a more appropriate model for obesity, metabolic syndrome, type 2 diabetes and the consequent complications is needed for this work. In 2004, PreClinOmics (PCO) began a promising program to develop a new mouse model without leptin/leptin- receptor and other genetic defects which would affect hypothalamic function, by crossing two inbred mouse models with the propensity to develop diet induced obesity with insulin resistance. The long-term goal of this project is to create a mouse model that will be accepted by the biotech or pharmaceutical industries, and the research community to advance the study of and the development of therapies for obesity, metabolic syndrome and type 2 diabetes in humans. Phase II of the project will focus on the continued development, defining, and characterization of this new obese mouse model. The project has four specific aims: 1) Continue development of the Fatzo mouse to achieve genetic and phenotypic homogeneity of traits for obesity and metabolic syndrome. Confirm normal function of LepR and Lep genes by experimental evidence of responsiveness to exogenous leptin. 2) Identify and confirm the presence of known components of human metabolic syndrome/type 2 diabetes in the Fatzo mouse. Components to be examined include reduced energy expenditure, dyslipidemia, hypertension, dysfunctional glucocorticoid regulation, low grade inflammation, beta cell dysfunction and activated renin-angiotensin-aldosterone-system (RAAS). 3) Confirm the models'responsiveness in prevention and treatment strategies to agents marketed for the clinical treatment of metabolic syndrome/type 2 diabetes. 4) Confirm the model's responsiveness to dietary manipulation to maintain the pre-diabetic state as well as to accelerate the progression to frank diabetes.

Public Health Relevance:
Research to identify new treatments for human obesity and its related conditions is hindered by the lack of relevant animal models. This effort will describe a new mouse model that reflects the human disease and is therefore applicable for the evaluation of potential treatments.